Catherine S Diefenbach
Laura and Isaac Perlmutter Cancer Center at NYU Langone · Academic and Community Cancer Research United · ECOG-ACRIN Cancer Research Group
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Catherine S Diefenbach as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:22 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT05272384 · Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell LymphomaNational Cancer Institute (NCI) · recruiting · Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma · principal investigator
- Ph2NCT04659044 · Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell LymphomaAcademic and Community Cancer Research United · terminated · Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma · principal investigator
- Ph1/Ph2NCT01896999 · Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin LymphomaNational Cancer Institute (NCI) · active not recruiting · Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma · principal investigator
- Ph1NCT01695941 · Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin LymphomaNational Cancer Institute (NCI) · active not recruiting · Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:22 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 3 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Protocol Review and Monitoring SystemP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · fiscal years 2023 · $54,216 awarded in 2023Grant number is on one of their registry trials
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Chromatin Architecture Regulatory Mechanisms in Pathogenesis of B-Cell LymphomasP01CA229086 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Effie Apostolou · fiscal years 2019 to 2026Named on NCT05272384
- Pathology Research Shared ResourceP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI THOMAS J FLOTTE · fiscal years 2019 to 2026Named on NCT04659044
- ECOG-ACRIN Network Group Operations CenterU10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2019 to 2026Named on NCT01896999
- ECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · fiscal years 2019 to 2026Named on NCT01896999
- Chemical Synthesis Shared ResourceP30CA013330 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI Juan Pablo Maianti · fiscal years 2019 to 2026Named on NCT01695941
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:22 UTC. The ranking covers the 200 most relevant of 14 PubMed records, and a shared surname and initials can bring in a namesake. All 14 on PubMed
- 137 citationsRCR 29.3
- Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.Lancet Haematol · 2020117 citationsRCR 4.1
- Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission.Clin Cancer Res · 200889 citationsRCR 1.7
- Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.Lancet Haematol · 202087 citationsRCR 3.4
- Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry.Leuk Lymphoma · 201754 citationsRCR 1.7
- 45 citationsRCR 1.2
- Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma.Blood Adv · 202326 citationsRCR 2.3
- Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial.Clin Lymphoma Myeloma Leuk · 202426 citationsRCR 3.0
- Distinct autoantibody profiles across checkpoint inhibitor types and toxicities.Oncoimmunology · 202412 citationsRCR 1.3
- A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies.Blood Adv · 20259 citationsRCR 2.3